A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8(+) T-cell-mediated anti-tumor immunity

作者：Song Ying Chyi; Cheng Han Yin; Leng Chih Hsiang; Chiang Sheng Kuo; Lin Chih Wei; Chong Pele; Huang Ming Hsi^*; Liu Shih Jen

来源：Journal of Controlled Release, 2014, 173: 158-165.

DOI：10.1016/j.jconrel.2013.10.027

• Adjuvant
• Immunotherapy
• Human papillomavirus (HPV)
• Cervical cancer
• CpG oligodeoxynucleotide

PELC is a novel emulsion-type adjuvant that contains the bioresorbable polymer poly (ethylene glycol)-block-poly (lactide-co-epsilon-caprolactone) (PEG-b-PLACL), Span (R) 85 and squalene. To investigate whether PELC is able to enhance CTL responses of antigens for treating tumor, peptides or protein antigens derived from HPV16 E7 were formulated with PELC nanoparticles and CpG oligodeoxynucleotide. We identified that PELC formulation could delay the release of antigens in vitro and in vivo. We assessed the immunogenicity of an H-2D(b)-restricted CTL epitope RAHYNIVTF (RAH) formulated with PELC or PELC/CpG and investigated the ability of these formulations to promote tumor regression. Following a single-dose subcutaneous injection in mice, we found that the RAH peptide formulated with PELC/CpG (RAH/PELC/CpG) resulted in increased numbers of IFN-gamma-secreting cells and RAH-specific CD8(+) T cells and an enhanced cytotoxic T cell response compared with RAH formulated with PELC or CpG alone. The tumor-bearing mice received a single-dose injection of RAH/PELC/CpG, which induced complete tumor regression. These results demonstrated that peptide antigen formulated with PELC/CpG nanoparticles is feasible for cancer immunotherapy.

• 出版日期2014-1-10
• 单位中国医科大学